索托维单抗对轻中度COVID-19高危患者住院或死亡的影响:一项随机临床试验
这项在巴西、加拿大、秘鲁、西班牙和美国57个中心开展的随机临床试验纳入1057例未住院的轻中度COVID-19且有至少1项进展危险因素的患者,评估单次静脉输注500 mg索托维单抗与安慰剂相比的疗效。结果显示,索托维单抗显著降低第29天全因住院超过24小时或死亡的复合终点(6/528[1%] vs 30/529[6%];校正RR 0.21[95%CI 0.09至0.50];P<.001)。
要点
- 索托维单抗组第29天全因住院超过24小时或死亡比例为1%,安慰剂组为6%。
- 调整后相对风险为0.21(95%CI 0.09至0.50),绝对差异为-4.53%(95%CI -6.70%至-2.37%),P<.001。
- 5项次要结局中4项在层级检验中达到统计学显著,支持索托维单抗用于未住院的轻中度COVID-19高危患者。
核心结论
- 在未住院的轻中度COVID-19且有疾病进展风险的患者中,单次静脉输注索托维单抗与安慰剂相比显著降低第29天全因住院或死亡的复合终点风险。
- 研究结果支持索托维单抗作为未住院的轻中度COVID-19高危患者的治疗选择,但其对研究完成后出现的SARS-CoV-2变异株的疗效尚不清楚。
研究设计与样本
- 随机临床试验,纳入1057例未住院、有症状的轻中度COVID-19且至少1项进展危险因素的患者。
- 研究在巴西、加拿大、秘鲁、西班牙和美国的57个中心开展,时间为2020年8月27日至2021年3月11日,随访数据收集至2021年4月8日。
- 患者按1:1随机接受静脉输注索托维单抗500 mg(n=528)或安慰剂(n=529)。
- 期中分析时因疗效达到预设标准而提前终止入组。
主要发现
- 患者中位年龄53岁(IQR 42-62),20%为65岁及以上,65%为拉丁裔;索托维单抗组中位随访103天,安慰剂组中位随访102天。
- 第29天全因住院超过24小时或死亡:索托维单抗组6/528(1%) vs 安慰剂组30/529(6%)(校正RR 0.21[95%CI 0.09至0.50];绝对差异-4.53%[95%CI -6.70%至-2.37%];P<.001)。
- 第29天急诊就诊、任何时长住院或死亡的复合终点:索托维单抗组13/528(2%) vs 安慰剂组39/529(7%)(校正RR 0.34[95%CI 0.19至0.63];绝对差异-4.91%[95%CI -7.50%至-2.32%];P<.001)。
- 进展为需补充氧气或机械通气的重度或危重度呼吸道COVID-19:索托维单抗组7/528(1%) vs 安慰剂组28/529(5%)(校正RR 0.26[95%CI 0.12至0.59];绝对差异-3.97%[95%CI -6.11%至-1.82%];P=.002)。
- 5项次要结局中4项在层级检验中达到统计学显著且支持索托维单抗。
关键数值与推荐
- 索托维单抗组不良事件发生率为22%,安慰剂组为23%。
- 索托维单抗组最常见不良事件为腹泻(n=8;2%),安慰剂组最常见不良事件为COVID-19肺炎(n=22;4%)。
临床怎么用
- 研究作者认为,研究结果支持索托维单抗作为未住院的轻中度COVID-19高危患者的治疗选择,但索托维单抗对研究完成后出现的SARS-CoV-2变异株的疗效尚不清楚。
局限性
- 研究因疗效在预设期中分析时提前终止入组。
- 索托维单抗对研究完成后出现的SARS-CoV-2变异株的疗效尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progression. OBJECTIVE: To evaluate the efficacy and adverse events of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial including 1057 nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for progression conducted at 57 sites in Brazil, Canada, Peru, Spain, and the US from August 27, 2020, through March 11, 2021; follow-up data were collected through April 8, 2021. INTERVENTIONS: Patients were randomized (1:1) to an intravenous infusion with 500 mg of sotrovimab (n = 528) or placebo (n = 529). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with COVID-19 progression through day 29 (all-cause hospitalization lasting >24 hours for acute illness management or death); 5 secondary outcomes were tested in hierarchal order, including a composite of all-cause emergency department (ED) visit, hospitalization of any duration for acute illness management, or death through day 29 and progression to severe or critical respiratory COVID-19 requiring supplemental oxygen or mechanical ventilation. RESULTS: Enrollment was stopped early for efficacy at the prespecified interim analysis. Among 1057 patients randomized (median age, 53 years [IQR, 42-62], 20% were ≥65 years of age, and 65% Latinx), the median duration of follow-up was 103 days for sotrovimab and 102 days for placebo. All-cause hospitalization lasting longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) (adjusted relative risk [RR], 0.21 [95% CI, 0.09 to 0.50]; absolute difference, -4.53% [95% CI, -6.70% to -2.37%]; P < .001). Four of the 5 secondary outcomes were statistically significant in favor of sotrovimab, including reduced ED visit, hospitalization, or death (13/528 [2%] for sotrovimab vs 39/529 [7%] for placebo; adjusted RR, 0.34 [95% CI, 0.19 to 0.63]; absolute difference, -4.91% [95% CI, -7.50% to -2.32%]; P < .001) and progression to severe or critical respiratory COVID-19 (7/528 [1%] for sotrovimab vs 28/529 [5%] for placebo; adjusted RR, 0.26 [95% CI, 0.12 to 0.59]; absolute difference, -3.97% [95% CI, -6.11% to -1.82%]; P = .002). Adverse events were infrequent and similar between treatment groups (22% for sotrovimab vs 23% for placebo); the most common events were diarrhea with sotrovimab (n = 8; 2%) and COVID-19 pneumonia with placebo (n = 22; 4%). CONCLUSIONS AND RELEVANCE: Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29. The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild to moderate COVID-19, although efficacy against SARS-CoV-2 variants that have emerged since the study was completed is unknown. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04545060.
引用
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022. PMID: 35285853. doi:10.1001/jama.2022.2832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。